

## Phylogica appoints new Scientific Advisory Board member

**PERTH, Australia, 12 January 2018:** Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), developer of a leading intracellular drug delivery platform technology, is pleased to announce the appointment of Professor Shohei Koide to the Scientific Advisory Board (**SAB**).

Together with the recent SAB appointments of Prof. Judy Lieberman and Dr. Stephen Doberstein, Professor Koide will serve as a strategic resource for Phylogica as the Company continues to develop its intracellular drug delivery technology.

Commenting on the appointment, Dr. Rob Hayes, Phylogica's CSO said, "We are delighted that Shohei has agreed to join our SAB. He brings deep expertise in cancer, protein design, protein engineering, biologics and drug discovery. His influence on the rational design of biologics is demonstrated in several important scientific papers and biotech companies which owe their existence to his early work."

Phylogica's CEO Stephanie Unwin said, "Professor Koide is a leading expert globally in the design of biologics, plus other fields highly relevant to the work of Phylogica. We are excited to have him join our SAB, and look forward to leveraging his valuable expertise as we progress toward commercialization of our platform and delivery of therapeutics into the intracellular environment."

A biography of Professor Shohei Koide is available below.

### **Biography**

Dr. Koide is Professor of Biologics Design in the Department of Biochemistry and Molecular Pharmacology at New York University School of Medicine, and Director of the Cancer Biologics platform at the Perlmutter Cancer Center at NYU Langone Health. Prior to joining NYU, he was Professor of Biochemistry and Molecular Biology at University of Chicago from 2002 to 2016. In addition, he served as a scientific co-director of the Chicago Biomedical Consortium, and also is a fellow of the American Association for the Advancement of Science.

Dr. Koide has been actively engaged in protein engineering and design over the last two decades. He is best known for his work in the development of "monobodies," designer binding proteins with antibody-like properties and for his contribution to the development of synthetic antibody technologies. His research seamlessly integrates rational design, directed evolution, structural biology and cell biology to design highly functional but still simple protein molecules. He has applied such synthetic proteins as powerful tools for addressing fundamental challenges in biology, medicine and chemistry. His team has developed monobody inhibitors to "undruggable" targets, such as RAS and protein phosphatases, which have inspired novel therapeutic strategies.

Dr. Koide earned his undergraduate B.S., graduate M.S. and post-graduate Ph.D. degrees at the University of Tokyo. He subsequently was a Human Frontier Science Program post-doctoral fellow at The Scripps Research Institute in La Jolla, CA and started his independent career as Assistant Professor of Biochemistry and Biophysics at the University of Rochester School of Medicine and Dentistry.

Dr. Koide has published more than 100 peer-reviewed articles in top-tier journals, including Nature, Cell, Science, Molecular Cell, Nature Methods and PNAS. His research has continuously been funded through the U.S. National Institutes of Health, and he holds several U.S. and overseas patents on findings resulting from his research.

**ENDS**

For further information, please contact:

**INVESTORS**

Stephanie Unwin  
CEO  
[stephanieu@phylogica.com](mailto:stephanieu@phylogica.com)  
0411 132 287

**MEDIA**

Ben Walsh  
WE Buchan  
[bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)  
0411 520 012

**About Phylogica**

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug

cargoes into cells, and the company's lead asset program has identified a Phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genentech.

### **Forward looking statements**

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

[www.phylogica.com](http://www.phylogica.com)

**Phylogica Ltd**

ABN 48 098 391 96